Somaxon to raise up to $35.2 million
This article was originally published in Scrip
Executive Summary
Somaxon Pharmaceuticals is to sell up to 4.6 million shares of its common stock, just days after its insomnia drug Silenor (low-dose doxepin) received US FDA approval.